All In Biotech

NDA 201849 · Fresenius Kabi USA

Glucagon

Glucagon Hydrochloride · Intramuscular, Intravenous, Subcutaneous, Intramuscular, Intravenous

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

May 8, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,154

249 Phase 3, 171 recruiting

FAERS reports

3,600

2,995 serious, 635 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2025.

Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ( 1.1 ) as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients ( 1.2 ) 1.1 Severe Hypoglycemia Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. 1.2 Diagnostic Aid Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

Mechanism: Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 9, 2019 Supplement 5 · Efficacy LetterLabel
  • May 8, 2015 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetter
2 products under this application
  • GLUCAGON · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL · POWDER, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Prescription
  • GLUCAGON · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL · POWDER, INTRAMUSCULAR, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Glucagon" as an intervention, any sponsor and status, largest first.

All 1,154 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea362
  • drug ineffective332
  • acute kidney injury323
  • hypotension298
  • condition aggravated257
  • toxicity to various agents237
  • haemoptysis224
  • anxiety221
  • hypoglycaemia207
  • pain in extremity207
  • asthma196
  • off label use193

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200524
200620
200726
200823
200949
201034
201153
201253
201354
201483
2015230
2016202
2017210
2018207
2019305
2020353
2021316
2022226
2023303
2024297
2025306
2026207

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,332 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.